CYCLERION THERAPEUTICS, INC. (KRSA) Return on equity 2019–2025
CYCLERION THERAPEUTICS, INC. (KRSA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-38.8%FY2025 · since FY2019: -125.9% → -38.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -38.8% | -4.3 pp |
| FY2024 | -34.5% | +12.1 pp |
| FY2023 | -46.6% | +375.1 pp |
| FY2022 | -421.7% | -314.7 pp |
| FY2021 | -107.0% | +23.7 pp |
| FY2020 | -130.8% | -4.9 pp |
| FY2019 | -125.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More KRSA financial trends
KRSA RevenueKRSA Net incomeKRSA Net marginKRSA Gross profitKRSA Gross marginKRSA Operating incomeKRSA Operating marginKRSA Operating cash flowKRSA Free cash flowKRSA Capital expendituresKRSA Stock buybacksKRSA Dividends paidKRSA Total assetsKRSA Total liabilitiesKRSA Shareholders’ equityKRSA overview →